Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Everpar Advisors LLC

Everpar Advisors LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 19.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 480 shares of the biopharmaceutical company’s stock after selling 113 shares during the period. Everpar Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $342,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of REGN. International Assets Investment Management LLC lifted its holdings in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $127,489,000. Icon Wealth Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after purchasing an additional 75,569 shares in the last quarter. State Street Corp increased its stake in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its holdings in Regeneron Pharmaceuticals by 57.7% during the second quarter. Epoch Investment Partners Inc. now owns 163,296 shares of the biopharmaceutical company’s stock worth $171,629,000 after purchasing an additional 59,745 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $693.23 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $744.16 and a 200-day simple moving average of $954.41. The company has a market cap of $76.18 billion, a price-to-earnings ratio of 17.15, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20.

Analyst Upgrades and Downgrades

REGN has been the subject of several research analyst reports. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Royal Bank of Canada dropped their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Oppenheimer cut their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $1,130.00 to $738.00 in a research report on Thursday. Finally, Citigroup dropped their price target on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.